Infliximab Biosimilar, Anti-human TNF alpha Antibody | Catalog C011P

Infliximab biosimilar CHO stable cell line is available for licensing to manufacture the Infliximab biosimilar protein. The research grade infliximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C011P
Product Name	Infliximab Biosimilar, TNF alpha Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-TNF alpha Chimeric Monoclonal Antibody
Summary	Recombinant Chimeric IgG1 Monoclonal Antibody.
Source/Host	Produced in the infliximab biosimilar CHO stable cell line.
Specificity	Specifically binds to the human TNF alpha.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
Formulation	0.2 µM filtered solution, pH 7.2, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.